« Previous Next » Biology of Blood and Marrow Transplantation
Volume 15, Issue 6 , Pages 671-678 , June 2009

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD

Suzanne van Dorp
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
- Department of Immunology, UMC Utrecht , The Netherlands
Floor Pietersma
- Department of Immunology, UMC Utrecht , The Netherlands
Matthias Wölfl
- Children's Hospital, University of Würzburg, Germany
Leo F. Verdonck
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
Eefke J. Petersen
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
Henk M. Lokhorst
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
Edwin Martens
- Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands
Matthias Theobald
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
Debbie van Baarle
- Department of Immunology, UMC Utrecht , The Netherlands
Ellen Meijer
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
Jürgen Kuball
- Department of Hematology and Van Creveld Clinic, UMC Utrecht, The Netherlands
- Department of Immunology, UMC Utrecht , The Netherlands
- Correspondence and reprint requests: Jürgen Kuball, MD, Department of Hematology, Department of Immunology, University Medical Centre Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands.

Received 16 October 2008 ,Accepted 16 February 2009.

B cell counts pre- and post-RICT in patients who received (white bars) and did not receive (black bars) Rtx within 6 months prior to RICT compared to a healthy control group (gray bar). Statistical an

B cell counts pre- and post-RICT in patients who received (white bars) and did not receive (black bars) Rtx within 6 months prior to RICT compared to a healthy control group (gray bar). Statistical analyses compare B cell counts of patients of each time point to B cell counts of the healthy control group. Counts before RICT (within 1 week), or months after RICT are indicated. Bars indicate median and range. Numbers indicate the number of samples measured per time point. Only significant changes (P < .05) are indicated. Statistical analyses were performed with a Mann-Whitney U-test.
- Full-Size Image
- Download to PowerPoint
1-Kaplan-Meier curves of aGVHD grade II-IV (A) and grade III-IV (B) in patients who received Rtx prior to RICT and in patients who did not. (C) Onset of aGVHD grade III-IV in patients who received Rtx

1-Kaplan-Meier curves of aGVHD grade II-IV (A) and grade III-IV (B) in patients who received Rtx prior to RICT and in patients who did not. (C) Onset of aGVHD grade III-IV in patients who received Rtx prior to RICT and in patients who did not.
- Full-Size Image
- Download to PowerPoint
1-Kaplan-Meier curves of total cGVHD (A) extensive cGVHD (B), and limited cGVHD (C) in patients who received Rtx prior to RICT and in patients who did not.

1-Kaplan-Meier curves of total cGVHD (A) extensive cGVHD (B), and limited cGVHD (C) in patients who received Rtx prior to RICT and in patients who did not.
- Full-Size Image
- Download to PowerPoint
Kaplan-Meier curves of PFS (A) and OS (B) in patients who received Rtx prior to RICT and in patients who did not.

Kaplan-Meier curves of PFS (A) and OS (B) in patients who received Rtx prior to RICT and in patients who did not.
- Full-Size Image
- Download to PowerPoint